Speaker Profile
M.D., Ph.D., CSO, VP of Product Strategy, Genomenon
Biography
Dr. Mark Kiel completed his M.D., Ph.D., and Molecular Genetic Pathology Fellowship at the University of Michigan, where his research focused on stem cell biology, genomic profiling of hematopoietic malignancies, and clinical bioinformatics. He is the founder and chief scientific officer at Genomenon, where he oversees the company's scientific direction and product development. A genomic intelligence company, Genomenon was founded by Mark in 2014 to address the challenge of connecting pharma researchers with evidence in the genomic literature to help diagnose and treat patients with genetic diseases and cancer.
Talk
Understanding Gene-Disease Relationships: A Novel and Actionable Approach
The increasing use of large gene panels for genetic diseases has created a strain on labs to interpret this data. There is a need to appreciate a wider array of gene-disease relationships to accommodate a more diverse set of diseases. We'll discuss this growing need, describe the challenges, and how to solve them at scale.
AI and Data Sciences Showcase:
Genomenon
Genomenon is a genomic intelligence company dedicated to improving the quality of patients’ lives by uncovering the genomic drivers of genetic disease and cancer. Blending the power of AI with genomic expertise, Genomenon simplifies complex genetic data into actionable insights for diagnosis and precision medicine.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2024 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
